Thursday, March 31, 2016

BRIEF-Corbus Pharmaceuticals announces addition of Phase 2 clinical protocol for resunab treatment to FDA IND

* Addition of Phase 2 clinical protocol for resunab treatment of systemic lupus erythematosus to FDA IND


Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)